Vincent Audard

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/164094/publications.pdf

Version: 2024-02-01

136950 197818 3,142 129 32 49 h-index citations g-index papers 139 139 139 3555 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Acute Renal Infarction. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 392-398.	4.5	135
2	Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease. Kidney International, 2013, 83, 511-516.	5.2	115
3	c-mip Impairs Podocyte Proximal Signaling and Induces Heavy Proteinuria. Science Signaling, 2010, 3, ra39.	3.6	99
4	Renal Lesions Associated with IgM-Secreting Monoclonal Proliferations. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 1339-1349.	4.5	89
5	Recent approaches to the pathogenesis of minimal-change nephrotic syndrome. Nephrology Dialysis Transplantation, 2003, 18, 245-248.	0.7	85
6	Daratumumab in Sensitized Kidney Transplantation: Potentials and Limitations of Experimental and Clinical Use. Journal of the American Society of Nephrology: JASN, 2019, 30, 1206-1219.	6.1	85
7	Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy. Kidney International, 2014, 85, 457-470.	5.2	84
8	Risk factors and outcome of focal and segmental glomerulosclerosis recurrence in adult renal transplant recipients. Nephrology Dialysis Transplantation, 2006, 21, 1053-1059.	0.7	83
9	Randall-type monoclonal immunoglobulin deposition disease: novel insights from a nationwide cohort study. Blood, 2019, 133, 576-587.	1.4	78
10	Six Months of Hydroxyurea Reduces Albuminuria in Patients with Sickle Cell Disease. Journal of the American Society of Nephrology: JASN, 2016, 27, 1847-1853.	6.1	75
11	B7–1 Blockade Does Not Improve Post–Transplant Nephrotic Syndrome Caused by Recurrent FSGS. Journal of the American Society of Nephrology: JASN, 2016, 27, 2520-2527.	6.1	75
12	Truncation of C-mip (Tc-mip), a New Proximal Signaling Protein, Induces c-maf Th2 Transcription Factor and Cytoskeleton Reorganization. Journal of Experimental Medicine, 2003, 198, 797-807.	8.5	72
13	Glomerular Lesions in Patients With Sickle Cell Disease. Medicine (United States), 2010, 89, 18-27.	1.0	68
14	Renal transplantation from extended criteria cadaveric donors: problems and perspectives overview. Transplant International, 2007, 21, 070915194042001-???.	1.6	65
15	Occurrence of minimal change nephrotic syndrome in classical Hodgkin lymphoma is closely related to the induction of c-mip in Hodgkin-Reed Sternberg cells and podocytes. Blood, 2010, 115, 3756-3762.	1.4	59
16	Acute Graft Pyelonephritis: A Potential Cause of Acute Rejection in Renal Transplant. Transplantation, 2005, 80, 1128-1130.	1.0	58
17	Acute kidney injury in sickle patients with painful crisis or acute chest syndrome and its relation to pulmonary hypertension. Nephrology Dialysis Transplantation, 2010, 25, 2524-2529.	0.7	56
18	NEPHRUTIX: A randomized, double-blind, placebo vs Rituximab-controlled trial assessing T-cell subset changes in Minimal Change Nephrotic Syndrome. Journal of Autoimmunity, 2018, 88, 91-102.	6.5	56

#	Article	IF	Citations
19	The spectrum of kidney biopsies in hospitalized patients with COVID-19, acute kidney injury and/or proteinuria. Nephrology Dialysis Transplantation, 2021, 36, 1253-1262.	0.7	54
20	APOL1 Polymorphisms and Development of CKD in an IdenticalÂTwin Donor and Recipient Pair. American Journal of Kidney Diseases, 2014, 63, 816-819.	1.9	51
21	Phospholipase A2 receptor and sarcoidosis-associated membranous nephropathy. Nephrology Dialysis Transplantation, 2015, 30, 1047-1050.	0.7	51
22	The Regulatory/Cytotoxic Graft-Infiltrating T Cells Differentiate Renal Allograft Borderline Change From Acute Rejection. Transplantation, 2007, 83, 341-346.	1.0	44
23	Renal Transplantation in Patients with Sarcoidosis. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 2101-2108.	4.5	43
24	Rituximab therapy prevents focal and segmental glomerulosclerosis recurrence after a second renal transplantation. Transplant International, 2012, 25, e62-e66.	1.6	43
25	Recurrence from primary and secondary glomerulopathy after renal transplant. Transplant International, 2012, 25, 812-824.	1.6	42
26	Immunopathogenesis of idiopathic nephrotic syndrome with relapse. Seminars in Immunopathology, 2014, 36, 421-429.	6.1	40
27	Rituximab in Membranous Nephropathy. Kidney International Reports, 2021, 6, 881-893.	0.8	39
28	Immunopathogenesis of Idiopathic Nephrotic Syndrome. Contributions To Nephrology, 2011, 169, 94-106.	1.1	38
29	Value of biomarkers for predicting immunoglobulin A vasculitis nephritis outcome in an adult prospective cohort. Nephrology Dialysis Transplantation, 2017, 33, 1579-1590.	0.7	37
30	Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?. Autoimmunity Reviews, 2020, 19, 102671.	5.8	37
31	Minimal Change Nephrotic Syndrome Associated With Non-Hodgkin Lymphoid Disorders. Medicine (United States), 2014, 93, 350-358.	1.0	36
32	T-cell phenotype in protocol renal biopsy from transplant recipients treated with belatacept-mediated co-stimulatory blockade. Nephrology Dialysis Transplantation, 2011, 26, 1087-1093.	0.7	34
33	Advagraf ^{\hat{A}^{\otimes}} , a once-daily prolonged release tacrolimus formulation, in kidney transplantation: literature review and guidelines from a panel of experts. Transplant International, 2016, 29, 860-869.	1.6	34
34	Podocyte Injury in Lupus Nephritis. Journal of Clinical Medicine, 2019, 8, 1340.	2.4	34
35	Intragraft Levels of Foxp3 mRNA Predict Progression in Renal Transplants with Borderline Change. Journal of the American Society of Nephrology: JASN, 2008, 19, 2277-2281.	6.1	33
36	Upregulation of c-mip is closely related to podocyte dysfunction in membranous nephropathy. Kidney International, 2013, 83, 414-425.	5.2	33

#	Article	IF	CITATIONS
37	Clinicopathological study of glomerular diseases associated with sarcoidosis: a multicenter study. Orphanet Journal of Rare Diseases, 2013, 8, 65.	2.7	32
38	Morbidity and mortality of sickle cell disease patients starting intermittent haemodialysis: a comparative cohort study with non―Sickle dialysis patients. British Journal of Haematology, 2016, 174, 148-152.	2 . 5	32
39	Kidney transplantation in patients with systemic sclerosis: a nationwide multicentre study. Transplant International, 2017, 30, 256-265.	1.6	30
40	Natural history and impact of treatment with tafamidis on major cardiovascular outcomeâ€free survival time in a cohort of patients with transthyretin amyloidosis. European Journal of Heart Failure, 2021, 23, 264-274.	7.1	30
41	Mycoplasma hominis infection in renal transplantation. Nephrology Dialysis Transplantation, 2002, 17, 495-496.	0.7	27
42	c-mip Down-Regulates NF-κB Activity and Promotes Apoptosis in Podocytes. American Journal of Pathology, 2012, 180, 2284-2292.	3.8	27
43	Upregulation of Nuclear Factor-Related Kappa B Suggests a Disorder of Transcriptional Regulation in Minimal Change Nephrotic Syndrome. PLoS ONE, 2012, 7, e30523.	2.5	26
44	Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast Nephropathy. Journal of Clinical Oncology, 2020, 38, 2647-2657.	1.6	24
45	Glomerular Collapse Associated With Subtotal Renal Infarction in Kidney Transplant Recipients With Multiple Renal Arteries. American Journal of Kidney Diseases, 2010, 55, 558-565.	1.9	22
46	First evidence of subclinical renal tubular injury during sickle-cell crisis. Orphanet Journal of Rare Diseases, 2014, 9, 67.	2.7	22
47	The Filamin-A is a partner of Tc-mip, a new adapter protein involved in c-maf-dependent Th2 signaling pathway. Molecular Immunology, 2004, 40, 1257-1261.	2.2	20
48	Arteriolar Hyalinization Predicts Delayed Graft Function in Deceased Donor Renal Transplantation. Transplantation, 2008, 86, 1002-1005.	1.0	20
49	An open-label randomized controlled trial of low-dose corticosteroid plus enteric-coated mycophenolate sodium versus standard corticosteroid treatment for minimal change nephrotic syndrome in adults (MSN Study). Kidney International, 2018, 94, 1217-1226.	5. 2	20
50	Sickle cell disease and albuminuria: recent advances in our understanding of sickle cell nephropathy. CKJ: Clinical Kidney Journal, 2017, 10, 475-478.	2.9	19
51	Causes of Death in Sickle Cell Disease Adult Patients: Old and New Trends. Blood, 2014, 124, 2715-2715.	1.4	19
52	B-Cell Dysregulation in Idiopathic Nephrotic Syndrome: What We Know and What We Need to Discover. Frontiers in Immunology, 2022, 13, 823204.	4.8	19
53	Arterioâ€venous fistula for automated red blood cells exchange in patients with sickle cell disease: Complications and outcomes. American Journal of Hematology, 2017, 92, 136-140.	4.1	18
54	Circulating plasmablasts and high level of BAFF are hallmarks of minimal change nephrotic syndrome in adults. Nephrology Dialysis Transplantation, 2021, 36, 609-617.	0.7	18

#	Article	IF	Citations
55	Continuous positive airway pressure for respiratory support during COVID-19 pandemic: a frugal approach from bench to bedside. Annals of Intensive Care, 2021, 11, 38.	4.6	18
56	Spectrum of adult Parvovirus B19 infection according to the underlying predisposing condition and proposals for clinical practice. British Journal of Haematology, 2015, 170, 192-199.	2.5	17
57	Repression of CMIP transcription by WT1 is relevant to podocyte health. Kidney International, 2016, 90, 1298-1311.	5.2	17
58	Epidemiology, Risk Factors, and Outcomes of Opportunistic Infections after Kidney Allograft Transplantation in the Era of Modern Immunosuppression: A Monocentric Cohort Study. Journal of Clinical Medicine, 2019, 8, 594.	2.4	17
59	Immunological risk in recipients of kidney transplants from extended criteria donors. Nephrology Dialysis Transplantation, 2010, 25, 2745-2753.	0.7	15
60	Survival and specific outcome of sickle cell disease patients after renal transplantation. British Journal of Haematology, 2019, 187, 676-680.	2.5	15
61	CMIP is a negative regulator of T cell signaling. Cellular and Molecular Immunology, 2020, 17, 1026-1041.	10.5	15
62	Long-Term Benefit of Mycophenolate Mofetil in Renal Transplantation. Transplantation, 2005, 79, S47-S48.	1.0	14
63	Intravenous immunoglobulin therapy in kidney transplant recipients with de novo DSA: Results of an observational study. PLoS ONE, 2017, 12, e0178572.	2.5	14
64	Myosteatosis as an independent risk factor for mortality after kidney allograft transplantation: a retrospective cohort study. Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 386-396.	7.3	14
65	Magnetic Resonance Imaging Assessment of Kidney Oxygenation and Perfusion During Sickle Cell Vaso-occlusive Crises. American Journal of Kidney Diseases, 2017, 69, 51-59.	1.9	13
66	Tubular Acidification Defect in Adults with Sickle Cell Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 16-24.	4.5	13
67	Malaria, Collapsing Glomerulopathy, and Focal and Segmental Glomerulosclerosis. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 964-972.	4.5	13
68	Successful Combined Heart and Kidney Transplantation in a Patient With Sickle-cell Anemia. Journal of Heart and Lung Transplantation, 2006, 25, 993-996.	0.6	12
69	C1q binding is not an independent risk factor for kidney allograft loss after an acute antibody-mediated rejection episode: a retrospective cohort study. Transplant International, 2017, 30, 277-287.	1.6	12
70	Safety of renal transplantation in patients with bipolar or psychotic disorders: a retrospective study. Transplant International, 2018, 31, 377-385.	1.6	12
71	Expression of CMIP in podocytes is restricted to specific classes of lupus nephritis. PLoS ONE, 2018, 13, e0207066.	2.5	12
72	Dexamethasone is associated with early deaths in light chain amyloidosis patients with severe cardiac involvement. PLoS ONE, 2021, 16, e0257189.	2.5	12

#	Article	IF	CITATIONS
73	De Novo Focal and Segmental Glomerulosclerosis After COVID-19 in a Patient With a Transplanted Kidney From a Donor With a High-risk APOL1 Variant. Transplantation, 2021, 105, 206-211.	1.0	12
74	Comparison of 3 Estimation Methods of Mycophenolic Acid AUC based on a Limited Sampling Strategy in Renal Transplant Patients. Therapeutic Drug Monitoring, 2009, 31, 224-232.	2.0	11
75	AA amyloidosis is an emerging cause of nephropathy in obese patients. European Journal of Internal Medicine, 2017, 39, e18-e20.	2.2	11
76	ANCA-Negative Pauci-immune Necrotizing Glomerulonephritis: A Case Series and a New Clinical Classification. American Journal of Kidney Diseases, 2022, 79, 56-68.e1.	1.9	11
77	History of extracardiac/cardiac events in cardiac amyloidosis: prevalence and time from initial onset to diagnosis. ESC Heart Failure, 2021, 8, 5501-5512.	3.1	11
78	Assessing Cardiac Amyloidosis SubtypesÂby Unsupervised Phenotype Clustering Analysis. Journal of the American College of Cardiology, 2021, 78, 2177-2192.	2.8	11
79	Immunoglobulin A nephropathy in association with inflammatory bowel diseases: results from a national study and systematic literature review. Nephrology Dialysis Transplantation, 2022, 37, 531-539.	0.7	10
80	Scleroderma renal crisis following mRNA vaccination against SARS-CoV-2. Kidney International, 2021, 100, 940-941.	5.2	10
81	Rituximab and Fibrillary Glomerulonephritis: Interest of B Cell Reconstitution Monitoring. Journal of Clinical Medicine, 2018, 7, 430.	2.4	9
82	Rituximab for recurrence of primary focal segmental glomerulosclerosis after kidney transplantation: Results of a nationwide study. American Journal of Transplantation, 2021, 21, 3021-3033.	4.7	8
83	Renal Diseases Associated with Hematologic Malignancies and Thymoma in the Absence of Renal Monoclonal Immunoglobulin Deposits. Diagnostics, 2021, 11, 710.	2.6	8
84	Renal diseases secondary to interferon- \hat{l}^2 treatment: a multicentre clinico-pathological study and systematic literature review. CKJ: Clinical Kidney Journal, 2021, 14, 2563-2572.	2.9	8
85	Intrarenal IFN- \hat{l}^3 mRNA Expression Differentiates Clinical and Subclinical Glomerulitis in Renal Transplant Recipients. Transplantation, 2011, 92, 170-175.	1.0	7
86	Acute Interstitial Nephritis With Predominant Plasmacytic Infiltration in Patients With HIV-1 Infection. American Journal of Kidney Diseases, 2012, 59, 711-714.	1.9	7
87	Creatinine clearance after cimetidine administration in a new short procedure: comparison with plasma and renal clearances of iohexol. CKJ: Clinical Kidney Journal, 2020, 13, 587-596.	2.9	7
88	Kidney–Targeted drug delivery systems based on tailor-made nanocapsules. Chemical Engineering Journal, 2021, 404, 126475.	12.7	7
89	Anti-CD38 therapy for PLA2R-positive membranous nephropathy resistant to conventional immunosuppression. Kidney International, 2022, 101, 416-418.	5.2	7
90	Idiopathic nephrotic syndrome relapse following COVID-19 vaccination: a series of 25 cases. CKJ: Clinical Kidney Journal, 2022, 15, 1574-1582.	2.9	7

#	Article	IF	CITATIONS
91	Abnormal RNA Processing and Altered Expression of Serin-Rich Proteins in Minimal-Change Nephrotic Syndrome. Pediatric Research, 2005, 57, 133-137.	2.3	6
92	Monotypic plasma cell interstitial nephritis as the only clinical manifestation in a patient with previously undiagnosed indolent multiple myeloma. Medicine (United States), 2016, 95, e4391.	1.0	6
93	Management of severe renal disease in anti-neutrophil-cytoplasmic-antibody-associated vasculitis: the place of rituximab and plasma exchange?. Rheumatology, 2022, 61, 4056-4064.	1.9	6
94	Acute Kidney Injury in Critically-Ill COVID-19 Patients. Journal of Clinical Medicine, 2022, 11, 2029.	2.4	6
95	Ischemic myopathy revealing systemic calciphylaxis. Muscle and Nerve, 2017, 56, 529-533.	2.2	5
96	Minimal change nephrotic syndrome in patients infected with human immunodeficiency virus: a retrospective study of 8 cases. BMC Nephrology, 2018, 19, 331.	1.8	5
97	Renal Infarction and Its Consequences for Renal Function in Patients With Cardiac Amyloidosis. Mayo Clinic Proceedings, 2019, 94, 961-975.	3.0	5
98	Severe Infection in Anti-Glomerular Basement Membrane Disease: A Retrospective Multicenter French Study. Journal of Clinical Medicine, 2020, 9, 698.	2.4	5
99	CMIP interacts with WT1 and targets it on the proteasome degradation pathway. Clinical and Translational Medicine, 2021, 11, e460.	4.0	5
100	<i>De novo</i> IgA vasculitis following adenovirus-based SARS-CoV-2 vaccination. CKJ: Clinical Kidney Journal, 2022, 15, 587-589.	2.9	5
101	Nephrotic Syndrome in Small Cell Lung Cancer and Induction of C-Mip in Podocytes. American Journal of Kidney Diseases, 2017, 69, 477-480.	1.9	4
102	Comparison of Plasma Clearance With Early-Compartment Correction Equations and Urinary Clearance in High GFR Ranges. Kidney International Reports, 2021, 6, 1622-1628.	0.8	4
103	Impact of preâ€eclampsia on renal outcome in sickle cell disease patients. British Journal of Haematology, 2021, 194, 1053-1062.	2.5	4
104	Apheresis in Adult With Refractory Idiopathic Nephrotic Syndrome on Native Kidneys. Kidney International Reports, 2021, 6, 2134-2143.	0.8	4
105	Prevalence and determinants of iron deficiency in cardiac amyloidosis. ESC Heart Failure, 2022, 9, 1314-1327.	3.1	4
106	A 59-kd Renal Antigen as a New Target for Rapidly Progressive Glomerulonephritis. American Journal of Kidney Diseases, 2007, 49, 710-716.	1.9	3
107	Myelodysplastic Syndrome in Hemodialysis Patients. Kidney International Reports, 2019, 4, 1175-1178.	0.8	3
108	Glomerulonephritis With Isolated C3 Deposits as a Manifestation of Subtotal Factor I Deficiency. Kidney International Reports, 2019, 4, 1354-1358.	0.8	3

#	Article	IF	CITATIONS
109	Outcomes of Older Patients (≥60 years) with New-Onset Idiopathic Nephrotic Syndrome Receiving Immunosuppressive Regimen: A Multicentre Study of 116 Patients. Journal of Clinical Medicine, 2019, 8, 298.	2.4	3
110	Reversible kidney iron accumulation in a patient with sickle cell disease treated with hydroxyurea. American Journal of Hematology, 2016, 91, 1283-1284.	4.1	2
111	Impact of renal function on hydroxyurea exposure in sickleâ€cell disease patients. British Journal of Clinical Pharmacology, 2021, 87, 2274-2285.	2.4	2
112	Long-term health-related quality of life outcomes of adults with pediatric onset of frequently relapsing or steroid-dependent nephrotic syndrome. Journal of Nephrology, 2021, , 1.	2.0	2
113	Causes of Death in 198 Sickle Cell Adult Patients: Old and New Trends. Blood, 2019, 134, 1031-1031.	1.4	2
114	Causes and Circumstances of Death: Analysis in 266 Sickle Cell Adult Patients. Blood, 2021, 138, 974-974.	1.4	2
115	Thrombospondin type-1 domain-containing 7A-related membranous nephropathy associated with glomerular AL amyloidosis. Pathology, 2022, 54, 654-657.	0.6	2
116	Evaluation of a new ELISA assay for monoclonal freeâ€light chain detection in patients with cardiac amyloidosis. EJHaem, 0, , .	1.0	2
117	Idiopathic light-chain proteinuria: Case report and review of the literature. American Journal of Hematology, 2004, 76, 293-294.	4.1	1
118	Comparison of Iohexol Plasma Clearances Calculated From 5 Early-Compartment Correction Equations With Urinary Clearance of Iohexol. Kidney International Reports, 2020, 5, 1842-1843.	0.8	1
119	Predictive Factors for Survival in Sickle Cell Disease: A Cohort Study Using Etendard Data. Blood, 2018, 132, 7-7.	1.4	1
120	Natural course and determinants of short-term kidney function decline in hereditary transthyretin amyloidosis: a French observational study. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 0 , 1 -11.	3.0	1
121	Face Transplantation Outcomes: Feasibility, Reproducibility and Efficacy. Plastic and Reconstructive Surgery, 2010, 126, 9.	1.4	0
122	Mott cell interstitial nephritis revealing Waldenström macroglobulinaemia. Annals of Hematology, 2018, 97, 1735-1736.	1.8	0
123	Hypermetabolic bilateral kidney enlargement associated with diffuse large B-cell lymphoma. Lancet Oncology, The, 2021, 22, e81.	10.7	0
124	The Role of c-mip in the Pathogenesis of Minimal Change Nephrotic Syndrome., 2016,, 81-91.		0
125	Arterio-Venous Fistula Is an Applicable Vascular Access for Erythracytapheresis in Patients with Sickle Cell Disease. Blood, 2016, 128, 4856-4856.	1.4	0
126	Study of Metabolic Acidosis in Sickle Cell Disease Patients. Blood, 2018, 132, 3667-3667.	1.4	0

#	Article	IF	CITATIONS
127	Spectre des atteintes rénales. , 2020, , 125-134.		0
128	Infections and Collapsing Glomerulopathy. American Journal of Kidney Diseases, 2020, 76, 600-601.	1.9	0
129	Glomerulonephritis with non-Randall-type, non-cryoglobulinemic monoclonal immunoglobulin G deposits [PGNMID and ITG]. CKJ: Clinical Kidney Journal, 0, , .	2.9	0